Multiple system atrophy: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• SNCA 1
• BDNF 0
• mTOR 0
• NLRP3 0
• PI3K 0
• TDP-43 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 234 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  NCT02897063· Vanderbilt University Medical Center· Updated 23 Oct 2026

  “enrollment goal was not met.”Registry text, quoted unchanged. Source

• Withdrawn

  High-Altitude Neurodegeneration Cohort (HANC) Study

  NCT07657520· West China Hospital· Updated 25 Aug 2026

  “Withdrawn due to internal administrative review”Registry text, quoted unchanged. Source

• Terminated

  Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)

  NCT05695378· Kainos Medicine Inc.· Updated 19 Sept 2024

  “Sponsor has decided to withdraw the study due to safety issue and re-initiate with a new clinical study”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes

  NCT07604883· International Institute of Molecular and Cell Biology in Warsaw· Source

• A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

  NCT06568237· Teva Branded Pharmaceutical Products R&D LLC· Source

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Source

• Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy

  NCT07518810· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

  NCT06706622· H. Lundbeck A/S· Source

• An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

  NCT07197866· Teva Branded Pharmaceutical Products R&D LLC· Source

• Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies

  NCT06683365· Craig van Horne, MD, PhD· Source

• Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease

  NCT06846658· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Source

• High-Altitude Neurodegeneration Cohort (HANC) Study

  NCT07657520· West China Hospital· Source

• The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).

  NCT07617012· XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Gene Expression Profiling 1
• Whole Genome Sequencing 3
• Exome Sequencing 1
• Proteomics 1
• Metabolomics 4
• Mass Spectrometry 1
• Immunohistochemistry 2
• Positron-Emission Tomography 21
• Magnetic Resonance Imaging 39
• Machine Learning 10
• Deep Learning 3
• Cohort Studies 10
• Genome-Wide Association Study 2

• Development of an Interpretable Deep Learning-Based Segmentation Algorithm for Automated Assessment of Oral Diadochokinesis in Progressive Neurological Diseases.

  J Speech Lang Hear Res, May 2026

• Deep Learning-Based Brainstem Segmentation and Multi-Class Classification for Parkinsonian Syndrome.

  J Magn Reson Imaging, Dec 2025

• NeuroMoE: A Transformer-Based Mixture-of-Experts Framework for Multi-Modal Neurological Disorder Classification.

  Annu Int Conf IEEE Eng Med Biol Soc, Jul 2025

See which targets of this disease your abstract mentions, and go to the people working on them.